purpura fulminans acute often fatal thrombotic disorder manifests blood spots bruising discolouration skin resulting coagulation small blood vessels within skin rapidly leads skin necrosis disseminated intravascular purpura fulminans caused defects protein c anticoagulant pathway identification cause purpura fulminans often depends patients age circumstances congenital inherited defects protein c activity autosomal dominant may partial severe loss hundreds natural mutations protein c gene proc acquired protein c deficiency caused either depletion available protein c plasma decreased protein c synthesis caused administration vitamin k antagonists severe liver failure complications purpura fulminans presenting feature severe acute sepsis neisseria meningitidis streptococcus pneumoniae group b streptococci less commonly haemophilus influenzae staphylococcus aureus plasmodium falciparum malaria infections particularly individuals cases combination sepsis partial congenital defect protein c anticoagulant pathway initiates purpura rare instances purpura fulminans autoimmune manifestation protein c protein normally benign infections chicken sometimes purpura fulminans unknown regardless underlying cause purpura fulminans mechanism disease similar deficiency protein c concentration decrease protein c activity promotes blood clotting cases severe sepsis widespread activation acute systemic inflammatory response including activation coagulation complement pathways well endothelial dysfunction activated protein c helps regulate systemic inflammatory response sepsis signalling inflammatory cytokines tumour necrosis factor mediate altered protein transcription systemic inflammatory response resulting decreased synthesis regulatory proteins antithrombin protein c protein increased synthesis prothrombotic proteins factor viii von willebrand factor fibrinogen activated protein c binds endothelial protein c receptor subsequently cleaves endothelial cell protease activated altering coagulation profiles downregulating proinflammatory proapoptotic mediators upregulation antiinflammatory antiapoptotic pathways stabilization endothelial cell barrier systemic coagulation activation may lead depletion circulating coagulation factors platelets subsequently lead early purpura fulminans lesion progression correlates histological appearance blockage small skin blood vessels blood clots causing capillary dilation congestion red blood cells later stage lesions irreversible endothelial ischaemic injury extravasation blood cells dermis gangrenous necrosis sometimes secondary depletion anticoagulant antiinflammatory proteins particular protein c cofactor protein may also promote thrombus formation inhibit fibrinolysis lead activation inflammatory early purpura fulminans lesions look similar traumatic skin bleeds purpuric rashes immune thrombocytopenic purpura thrombotic thrombocytopenic purpura however purpura fulminans rapidly progress necrosis whereas purpuric rashes cases differential diagnoses may distinguished purpura fulminans clinical laboratory initial appearance purpura fulminans lesions welldemarcated erythaamatous lesions progress rapidly develop irregular central areas blueblack haemorrhagic advancing areas necrosis often surrounded thin border erythaema fades adjacent unaffected skin haemorrhage necrotic skin causes purpura fulminans lesions become painful dark raised sometimes vesicle blister bulla distribution purpura fulminans lesions may different according underlying purpura fulminans severe sepsis typically develops distal extremities progresses proximally appears generalised diffuse rash affecting whole body cases severe inheritable protein c deficiency purpura fulminans disseminated intravascular coagulation manifests within hours days cardinal features purpura investigations disseminated intravascular coagulation prolonged plasma clotting times thrombocytopenia reduced plasma fibrinogen concentration increased plasma fibrindegradation products occasionally microangiopathic people severe congenital protein c deficiency protein c replacement therapies available indicated approved use united states europe prevention purpura fulminans protein c replacement often combination anticoagulation therapy injectable low molecular weight heparin oral initiating warfarin therapy days therapeutic heparin may administered prevent warfarin necrosis progressive recurrent thrombotic amount fresh frozen plasma required reverse disseminated intravascular coagulation associated purpura fulminans may lead complications fluid overload death especially transfusionrelated acute lung injury exposure multiple plasma donors time increases cumulative risk transfusionassociated viral infection allergic reaction donor proteins found fresh frozen allergic reactions alloantibody formation also potential complications protein replacement concomitant warfarin therapy subjects congenital protein c deficiency associated increased risk warfarin skin early stage sepsisassociated purpura fulminans may reversible quick therapeutic treatment mainly removing underlying cause degree clotting abnormalities supportive treatment antibiotics volume expansion tissue oxygenation etc thus treatment includes aggressive management septic statecitation needed purpura fulminans disseminated intravascular coagulation urgently treated fresh frozen plasma mlkg every hours andor protein c concentrate replace procoagulant anticoagulant plasma proteins depleted disseminated intravascular coagulation protein c plasma steady state half life therefore patients severe protein c deficiency presenting purpura fulminans treated acutely initial bolus protein c concentrate iukg followed iu kg every total iukg protein c concentrate mlkg fresh frozen plasma increase plasma concentration protein c cases comorbid pathological bleeding may require additional transfusions platelet concentrate mlkg cryoprecipitate established soft tissue necrosis may require surgical removal dead tissue fasciotomy amputation reconstructive purpura fulminans lesions established often progress within hours fullthickness skin necrosis softtissue necrosis purpura fulminans lesions progress fullthickness skin necrosis healing takes weeks leaves large without treatment necrotic soft tissue may become gangrenous leading loss purpura fulminans often accompanied microvascular thrombosis haemorrhagic infarction tissues lungs kidneys central nervous system adrenal glands leading multiple organ failure causes initial high mortality longterm morbidity survivors purpura fulminans may also lead severe large vessel venous thrombosis untreated early purpura fulminans secondary severe infection cases homozygous protein c deficiency episodes purpura fulminans thrombotic events moreover infant survival due maintenance replacement therapy often associated intellectual disability visual postinfection purpura fulminans new lesions occur neutralising autoantibodies present weeks multidisciplinary care team usually required rehabilitation purpura purpura fulminans rare commonly occurs babies small also rare manifestation adults associated severe example meningococcal septicaemia complicated purpura fulminans cases among purpura fulminans associated congenital inherited protein c deficiency occurs live due rarity purpura fulminans occurrence vulnerable patient groups like children research condition limited evidence based knowledge scarcecitation needed purpura fulminans first described guelliot httpsenwikipediaorgwikipurpuragangrenosa